首页 › 期刊 › 医学 › Journal of Clinical Oncology
Journal of Clinical Oncology
出版商:American Society of Clinical Oncology · ISSN:0732-183X, 1527-7755 · 国家/地区:US · 类型:journal · 创刊:1983 · 官网:http://www.jco.org/
研究主题:Lung Cancer Treatments and Mutations · Cancer Treatment and Pharmacology · Cancer Genomics and Diagnostics · Colorectal Cancer Treatments and Studies · Cancer Immunotherapy and Biomarkers
核心指标
- 影响因子(JCR 2025):44.700
- JCR 分区:Q1(ONCOLOGY)
- 中科院分区(2025):医学 1区(Top);小类:ONCOLOGY 肿瘤学 1区
- 新锐分区(2026):医学 1区
- SJR:4.648(Q1)
- h-index:740
- i10 指数:33395
- 近两年篇均被引:1.67
- 载文量 174162 · 总被引 4490973
逐年趋势
- 近年影响因子:2021 50.7 → 2022 45.3 → 2023 42.1 → 2024 41.9 → 2025 44.7
- 近年 SJR:2021 9.38(Q1) → 2022 10.2(Q1) → 2023 10.6(Q1) → 2024 11.2(Q1) → 2025 4.65(Q1)
投稿参考
- 投稿人评价:2.7 分(4 条评价)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- Kidney International Supplements — IF 89.6 · JCR Q1 · 中科院2区
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
- World Psychiatry — IF 65.8 · JCR Q1 · 中科院1区(Top)
常见问题
《Journal of Clinical Oncology》的影响因子是多少?
根据 JCR 2025 年数据,《Journal of Clinical Oncology》的最新影响因子(IF)为 44.700。
《Journal of Clinical Oncology》是几区期刊?
《Journal of Clinical Oncology》中科院分区(2025年版)为医学1区(Top 期刊),JCR 分区为 Q1。
本刊近期代表论文
- Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01. (2026 · 被引 9)
- Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. (2026 · 被引 9)
- The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease (2026 · 被引 8)
- Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials. (2026 · 被引 7)
- International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR (2026 · 被引 5)
- Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) (2026 · 被引 5)